@freddyeescorcia.bsky.social thank you for sharing this discussion.

@atoosarabiee.bsky.social this was a 4 part series (m.youtube.com/results?sp=m...) and we had a chance to have Med Onc, Hepatologist, IR, and RadOnc as part of the panel (having a transplanter/SurgOnc would have been amazing).

7. Role of ctDNA in CRC: #BESPOKE & @SWOG 80702 trial in Stage II/III CRC

- ctDNA+ remains prognostic for poor outcomes
- With all the data here at #GI25 on ctDNA, outside trials, how are you using this today in our clinic?

8/8

6. #BREAKWATER: Ph 3, Enco + Cetux + mFOLFOX vs SoC in BRAFV600E mCRC

- ORR 61% vs 40%
- Interim OS at 12mos 79.5% vs 66%
- Gr≥3 AEs: 37.7% vs 34.6%
- New SoC for BRAFV600E

7/8

5. #Checkmate8HW: Ph 3, dMMR/MSI-H unresectable or mCRC, Ipi (1mg/kg) + Nivo (240mg) Q3W for 4 cycles and then Nivo alone vs Nivo:

- mPFS NR for Ipi/Nivo vs 39·3 months
- ORR: 71% vs 58%
- Any grade AEs 81% from Ipi/Nivo vs 71% Nivo alone. 3 Rx related deaths.

6/8

4. #StarterNET: Ph 3, unressctable/recurrent non functional G1/2 GEP NET, 1L Lanreotide + everolimus vs everolimus

- Improved ORR (23% vs 8.3%)
- Improved PFS in all subsets w/ combo
- No OS difference at 1 year

5/8